Cannvas Signs Definitive Contract with MM Patient Relief as Exclusive Cannabis Education Provider

Cannyas. Me Exclusive Provider of Cannabis Education to All MMPR Members

TORONTO, May 21, 2019 /CNW/ - Cannvas MedTech Inc. ("Cannvas" or the "Company") (CSE: MTEC) (Frankfurt: 3CM) (OTCPK: CANVF), a leading digital cannabis educator and business technology company, is pleased to announce the signing of a definitive contract positioning Cannvas.Me as the exclusive provider of cannabis education and information to members of Medical Marihuana Patient Relief Inc. ("MM Patient Relief"), a private, locally-owned business based in Tecumseh, Ontario focused on creating high-quality, in-demand medical cannabis strains.

"We are thrilled to join MM Patient Relief in their mission to become a leading licenced producer of medical cannabis as we share similar goals of delivering physician-backed alternative therapy solutions to traditional pharmaceuticals using the power of data and analytics to offer a more personalized health care experience," said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. "Working with Cannvas enables MM Patient Relief members to access evidence-based cannabis education through the Cannvas.Me platform directly through the MM Patient Relief web portal, engaging members in active learning and providing a resource for those curious to learn more about the potential health benefits of cannabis."

Established in 2014, Medical Marihuana Patient Relief Inc. is currently in the final stages of review and approval under Health Canada's MMPR/ACMPR (Access to Cannabis for Medical Purposes Regulations). Once approved, it plans to use its proprietary technology to increase the crop yield and quality of cannabis produced in its newly-renovated stand-alone 10,000 sq.ft. building in Tecumseh, Ontario.

"MM Patient Relief understands how vital it is for Canadians to clearly understand their health care options amid an ever-changing medical landscape and learn whether cannabis is a viable alternative treatment that fits within their lifestyle," said Daniel Davidzon, Director of Strategy and Education, Cannvas MedTech Inc. "By providing its members with physician-backed and educator-approved cannabis education through the Cannvas.Me platform, MM Patient Relief helps empower its clients to make better decisions about their own well-being as they navigate news and articles pertaining to cannabis and its potential health benefits."

Once fully integrated with the MM Patient Relief portal, members will be able to Cannvas. Me content from anywhere in the world. Cannvas. Me will work closely with MM Patient Relief's partner network to source information and collaborate on articles to meet the needs of MM Patient Relief clients across Canada.

About Medical Marihuana Patient Relief

Established in 2014, Medical Marihuana Patient Relief Inc. (MMPatient Relief) is a private, locally-owned business based in Tecumseh, Ontario focused on creating high-quality, in-demand medical cannabis strains for pain, arthritis, and cancer. Using advanced cultivation methods that maximize production and have increased the number of yearly crop cycles from four to six, MM Patient Relief is in the final stage of Health Canada MMPR / ACMPR (Access to Cannabis for Medical Purposes Regulation) approval and finalizing construction of its state-of-the-art stand-alone facility. For more information: www.mmpatientrelief.com

About Cannvas MedTech Inc.

Cannvas MedTech is a leading digital cannabis education and business technology company within the health sciences space. We design and build patient-centric platforms that enable our partners to harness the power of data to truly understand their customers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

SOURCE Cannvas MedTech Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/21/c1803.html

%SEDAR: 00044276E

For further information: Visit cannvas.com

CO: Cannvas MedTech Inc.

CNW 08:00e 21-MAY-19